Etoposide

Catalog No.S1225 Synonyms: VP-16, VP-16213

Etoposide Chemical Structure

Molecular Weight(MW): 588.56

Etoposide is a semisynthetic derivative of podophyllotoxin, which inhibits DNA synthesis via topoisomerase II inhibition activity.

Size Price Stock Quantity  
In DMSO USD 91 In stock
USD 70 In stock
USD 280 In stock
USD 690 In stock
USD 990 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

5 Customer Reviews

  • ABT-199 synergizes strongly with lymphoma chemotherapy agents that affect MCL1 levels. Viability and CI vs Fa after 24-h exposure to etoposide alone or in combination with ABT-199 in Riva, U2932 and VavP-Bcl2/c-MYC murine tumor cells. Viability shown at 500 nM.

    Leukemia, 2015, 29: 1702–1712. Etoposide purchased from Selleck.

    Dox promotes formation of DNA DSBs in primary neurons. (A) Cortical neurons at 28–32 DIV were treated with a vehicle or with Dox (0.1 μ M) or with DNA damaging drug etoposide (5 μ M) overnight, fixed, and stained for a marker of DSBs phosphorylated histone H2A variant X, γ H2A.X (green), MAP2c (red), and with the nuclear Hoechst dye (blue), and imaged. The neuronal nucleus is enlarged on the Dox panel to illustrate the γ H2A.X puncta. Note the green nuclear staining in cells treated with Dox and etoposide. Also note the reduced dendritic arborization in neurons treated with Dox and etoposide. Scale bar is 20 μm.

    Sci Rep, 2016, 6:25705.. Etoposide purchased from Selleck.

  • Viability of U87 cells(C) assessed by the Alamar blue assay, 72 h after transfection with siRNA anti-survivin (siSURV) or with siMUT and/or cell incubation with the chemotherapeutical drugs etoposide (ETO) and Bliss interaction index (D) determined for the combined effects on cell viability of survivin silencing plus treatment with each drug. Cells were transfected, for 4 h, with (14Ser)2N5/siRNA/HL complexes and, after an additional period of 20 h, cells were incubated with 1.5 μM ETO (C) for 48 h. Results, representative of at least three independent experiments, are expressed as a percentage of the nontreated control cells. Combined treatment (dotted bar) was compared with the single drug treatment (gray bar) (**p < 0.01, ***p < 0.001) and the Bliss interaction index of each combined treatment was compared with the theoretical value expected for an additive effect (1.0) (#p < 0.05, ns, non-significant).

    Eur J Pharm Biopharm, 2016, 104:7-19.. Etoposide purchased from Selleck.

    Cellular biomarker responses in HT29 cells exposed to various cytotoxic chemotherapeutic agents in combination with the Chk1 inhibitor V158411. HT29 cells were exposed to the combination GI80 of gemcitabine (0.2 uM), camptothecin (0.44 uM), cisplatin (68 uM), oxaliplatin (131 uM), doxorubicin (1.2 uM) or etoposide (59 uM) for 18 hours followed by DMSO (-) or 400 nM V158411 (+) for a further 24 hours. Protein expression was characterized by immunoblotting.

    BMC Cancer 2014 14, 483. Etoposide purchased from Selleck.

  • (c) and (d) Effects of fractions C4 and C5 on topoisomerase II activity. Topoisomerase II activity was measured by plasmid DNA cleavage assay. DNA bands were visualized using UV light and the intensity of linear DNA band in each lane was measured using imageJ software. Lane 1: plasmid PBR322DNA. Lane 2: control, topoisomerase II + plasmid PBR322DNA. Lanes 3, 4, and 5: 40, 20, and 10 μg/mL fraction C4 + plasmid PBR322DNA, respectively. Lanes 6, 7, and 8: 40, 20, and 10 μg/mL fraction C5 + plasmid PBR322DNA, respectively. Lane 9: 100 μM etoposide + plasmid PBR322DNA. The data in different groups were expressed as the mean ± SD from 3 experiments. Statistical difference between groups was assessed by t-test using SPSS 20.0. ∗∗P < 0.01 versus the control group.

    Evid Based Complement Alternat Med, 2017, 2017:1456786. Etoposide purchased from Selleck.

Purity & Quality Control

Choose Selective Topoisomerase Inhibitors

Biological Activity

Description Etoposide is a semisynthetic derivative of podophyllotoxin, which inhibits DNA synthesis via topoisomerase II inhibition activity.
Targets
Topo II [2]
(Cell-free assay)
In vitro

Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA, which induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle. [1] Etoposide inhibits the growth of murine angiosarcoma cell line (ISOS-1) in a 5 days-period with IC50 of 0.25 μg/mL. Cell growth of normal murine microvascular endothelial cells (mECs) is less sensitive to Etoposide with IC50 of 10 μg/mL). [2] Etoposide treated for 6 hr inhibits colonies of tetraploid variant of the human leukemic lymphoblast line CCRF-CEM with IC50 of 0.6 μM. [3] Etoposide treated for 2 hr inhibits growth of human pancreatic cancer cell line Y1, Y3, Y5, Y19, YM. YS, and YT with IC50s of 300 μg/mL, 300 μg/mL, 300 μg/mL, 91 μg/mL, 0.68 μg/mL, 300 μg/mL, 300 μg/mL, and 260 μg/mL, respectively. [4] Etoposide exposed for 1 hr inhibits growth of human glioma cell lines CL5, G142, G152, G111, and G5 with IC50 of 8, 9, 9.8, 10, and 15.8 μg/mL respectively for 12 days. Under same condition, the IC90 value is attained in cell lines CL5, G152, G142, and G111 at 26, 27, 32, and 33 μg/mL. Etoposide inhibition of topoisomerase II is homogeneous for each cell. The average inhibition rates are 15%, 21.8%, 31.8%, 41.5%, and 49.5% for 1, 2, 4, 8, and 16 μg Etoposide, respectively. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Kelly MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPtTWM2OD1yLkGy5qCKyrIkgJmwMlAyKM7:TR?= NWjLOHBmOjV7NkCyPFI>
KellyCis83 NE\uSHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\WcplKSzVyPUCuNVbjiIoEsfMAjVAvODJizszN MnHtNlU6PjB{OEK=
SK-N-AS M2TIdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkS0TWM2OD1yLkK05qCKyrIkgJmwMlA{KM7:TR?= Mnv6NlU6PjB{OEK=
SK-N-ASCis24 NV3ZZVROT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlHYTWM2OD1yLkW35qCKyrIkgJmwMlEyKM7:TR?= MXyyOVk3ODJ6Mh?=
U87 NGnpdGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1vRNFAuPTBizszN Mk[1OFghcA>? NVH3OIFR\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JJdpcWOqIHPhckBj\SCnbnjhcoNm\CCkeTDzbYxq[mmwaX6= MoDONlU4PTB{N{O=
HCT116 M{nUOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHSwO48xNjVvMj61JO69VQ>? NULvU4lUPDkEoHlCpC=> NFzOSWxKSzVyPUGuO|PDqMLzwrCwMlIyyqEQvF2= NYjFNmNNOjV5NE[3OlM>
HT-29 NWHXcGI6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV[wMlUuOi53IN88US=> MXW0POKhcMLi M1PxXWlEPTB;Nz6yxsDDucLiMT6wOOKh|ryP NHXvcoczPTd2Nke2Ny=>
Caco2 NHvRNJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVjjOGlPOC53LUKuOUDPxE1? M4\XWFQ5yqCqwrC= MlPETWM2OD15LkK2xsDDucLiMT62POKh|ryP MWOyOVc1Pjd4Mx?=
COLO 205 NEnTS45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHjydIwxNjVvMj61JO69VQ>? NHnTN5A1QMLiaNMg MoLFTWM2OD1zLk[xxsDDucLiMD6wNuKh|ryP NGXWUmszPTd2Nke2Ny=>
SW480 NH7oe25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{PrVVAvPS1{LkWg{txO MnjHOFjDqGkEoB?= NXznW4VjUUN3ME20MlkzyqEEsdMgNE4{O8LizszN NVj3d5ljOjV5NE[3OlM>
HEK293T M1G2O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV[xMVUh|ryP NGnBPXU1QMLiaNMg MYfJR|UxRTJwNENCpOKyyqByLkC1xsDPxE1? NYjrSpNbOjV5NE[3OlM>
Hep3B  MWDGeY5kfGmxbjDBd5NigQ>? MlTwNVAh|ryP M4W3W|Q5yqCqwrC= NVLhWGQ5emWmdXPld{B1cGViZX7oZY5kcW6pIHXm[oVkfCCxZjDCUXAuPg>? MlO4NlU3OzN3NkS=
Hep3B  MVLGeY5kfGmxbjDBd5NigQ>? NIP4eJYxNjFvMUCg{txO MkjLNlQhcA>? NVrDW5RPe3WycILld5NmeyC2aHWg[ZhxemW|c3nvckBw\iCqZYDjbYRqdiCvUl7B NYr1fnpwOjV4M{O1OlQ>
HEK293 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\pcWlEPTB;Nz6xOOKhyrIEoECuN|bDqM7:TR?= MXyyOVYxOzF{Mh?=
DU145 NYS2cJVzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTJwMklCpOKyyqByLkC0xsDPxE1? NGDYNJgzPTZyM{GyNi=>
HCT15 NFHZVWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvNTWM2OD1yLkixxsDDucLiMD6wNeKh|ryP MojLNlU3ODNzMkK=
T47D NH3ScZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTNwMUlCpOKyyqByLkGxxsDPxE1? M1m2XVI2PjB|MUKy
SMMC-7721 M3\j[mZ2dmO2aX;uJGF{e2G7 NFnacow1OCEQvF2= NI\KVXE1QCCq NFTMSYFFVVOR MoSzbY5lfWOnczFOt2gzSVhiZn;jbUBnd3KvYYTpc44> M3zPblI2PTR2M{[x
MDA-MB-231 NIPDTWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFrTZmc4OsLiaB?= M3;hfGlEPTB;MkGuNuKhyrIEoESuNuKh|ryP MnjONlU1QDZ{MUm=
MCF-7 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVG3NuKhcA>? MkXpTWM2OD1zMD65xsDDucLiMj6xxsDPxE1? NHHpcmwzPTR6NkKxPS=>
Jurkat M4XNRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1XYTVczyqCq NVjYWW4yUUN3ME2xMlLDqMLzwrCxMlXDqM7:TR?= NYLrfWd5OjV2OE[yNVk>
HeLa M{Dhd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1zrRVczyqCq MXjJR|UxRTNwOdMgxtHDqDJwM9Mg{txO NX7tb2RCOjV2OE[yNVk>
MCF7  MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFvTd|M2NTFyMDFOwG0> MXi3JIQ> MmDRbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NXXj[pJ4OjV2N{K2NVk>
K562 NXr0epRUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkLiO|LDqGh? MXLJR|UxRTBwMkpCpO69VQ>? MYSyOVI5OjZ3Mx?=
K/VP.5 NFTHPWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoXSO|LDqGh? Mle2TWM2OD12LkpCpO69VQ>? M1e5VlI2Ojh{NkWz
SH-EP  MoTFSpVv[3Srb36gRZN{[Xl? MUCyNOKh|rypL33s NYLUT|l{OjUEoHi= MnTSbY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mJIVv\G:pZX7veZMhTEWSUB?= M{LVXVI2OjZzOUix
SCC25 NHH1b2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFL3NIwzPMLiaB?= MmrlTWM2OD12Mz6zxsDDucLiMT6xNuKh|ryP NGfZV4szPTJ{MEeyPS=>
CAL27 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXrNlTDqGh? NXLCbXBZUUN3ME21Nk4yyqEEsdMgNU4xQcLizszN MV:yOVIzODd{OR?=
FaDu NFfJe29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4XKeFI1yqCq NHnm[npKSzVyPUK1Mlg6yqEEsdMgNU4yO8LizszN M1eyU|I2OjJyN{K5
SCC25 NEKySIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml2zOFjDqGh? NFrWe21KSzVyPUKwMlg3yqEEsdMgNU4xP8LizszN M3PzOlI2OjJyN{K5
CAL27 NYj0eHNpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHLyfoU1QMLiaB?= Mn3oTWM2OD1zOD6yOOKhyrIEoEGuNVXDqM7:TR?= MnriNlUzOjB5Mkm=
FaDu M2fDUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jW[VQ5yqCq MVvJR|UxRTZwNERCpOKyyqBzLkGzxsDPxE1? M3;0elI2OjJyN{K5
SCC25 NXf1WWpYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17HbVczyqCq NHnLdZVKSzVyPUiuOFHDqMLzwrCxMlEyyqEQvF2= MV2yOVIzODd{OR?=
CAL27 NHrLc|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUnlVHd2PzMEoHi= NFPVeVhKSzVyPUSuNlfDqMLzwrCxMlE1yqEQvF2= NGG3TWMzPTJ{MEeyPS=>
FaDu NVTB[GFtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlrhO|LDqGh? MoKzTWM2OD13LkCyxsDDucLiMT6xOeKh|ryP MkLZNlUzOjB5Mkm=
MCF-7 NVXqdJlwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkfuOFjDqGkEoB?= MlPsSG1UVw>? MU\JR|UxRTdwMtMgxtHDqDBwONMg{txO NWSzWY5HOjV{MU[zO|g>
T-47D M13LVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjXWpdUPDkEoHlCpC=> MkPpSG1UVw>? MYDJR|UxRTdwN9MgxtHDqDBwN9Mg{txO NV3TcoJKOjV{MU[zO|g>
MDA-MB-231 MljaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4XLVVQ5yqCqwrC= M1i0ZmROW09? NYHMSZdZUUN3ME2xNk45yqEEsdMgNU4xyqEQvF2= NGrKSHMzPTJzNkO3PC=>
DU145 MULBdI9xfG:|aYOgRZN{[Xl? NVLwZ2REOTBvMUCwJO69VQ>? MmriPEBp MXfEUXNQ NYL2ephTcW6mdXPld{Bk\WyuIHTlZZRpKHOrZ37p[olk[W62bImgbY4h[SC4ZYL5JIxwfyClb37j[Y51emG2aX;u NGL1W2gzPTF2OU[4NS=>
DU145 stem-like NFqydplCeG:ydH;zbZMhSXO|YYm= Mn;tNVAuOTByIN88US=> M3r6clghcA>? Moq2SG1UVw>? NHXlT3ZqdmS3Y3XzJINmdGxiZHXheIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NFzUe|QzPTF2OU[4NS=>
DU145 NHH6UGZHfW6ldHnvckBCe3OjeR?= MXGxNE0yODBizszN M3LDRVIhcA>? M3i4V2ROW09? NXLDZVRLcW6lcnXhd4V{KHSqZTDwR2hMOSCneIDy[ZN{cW:wIHHu[EBl\WO{ZXHz[ZMhfGinIIDDTGsyKGW6cILld5Nqd25iaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NEDCW|EzPTF2OU[4NS=>
DU145 stem-like NXfLNndETnWwY4Tpc44hSXO|YYm= NIW1ZmMyOC1zMECg{txO NUTSfHgxOiCq MoDYSG1UVw>? NHz5PJRqdmO{ZXHz[ZMhfGinIIDDTGsyKGW6cILld5Nqd25iYX7kJIRm[3KnYYPld{B1cGVicFPIT|Eh\XiycnXzd4lwdiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NFHmdZMzPTF2OU[4NS=>
UW228-3 MljTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVzjcWVpOC5yMT2zNFAh|ryP MWC0PEBp MV3EUXNQ M{jrTmlEPTB;MD65PeKh|ryP NYnJepdEOjVzMUmxPFU>
NSCs NU\ic4lqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXKOVNOOC5yMT2zNFAh|ryP NYTNOZdKPDhiaB?= M3;ENmROW09? NHfpWpJKSzVyPUCuN{0{yqEQvF2= MUGyOVEyQTF6NR?=
MKL-1  MljRSpVv[3Srb36gRZN{[Xl? MU[xNE0yODByIH7N NEPEVIk1KGR? NVvafGJvcW6mdXPld{B1cGViaX7keYN1cW:wIH;mJG1JSy2LIHX4dJJme3Orb36= NYPMbWpnOjVzMU[3OVQ>
MCF7 EV MWfGeY5kfGmxbjDBd5NigQ>? M3XKWlExNTFyMDFOwG0> NGC2O3gz6oDLaB?= NYPIXGZCcW6mdXPld{Bxem:mdXP0bY9vKG:owrFOt2gzSVh? NHrGTpYzPTB6OEKwNy=>
MCF 7BMI1 M{X5UGZ2dmO2aX;uJGF{e2G7 MVmxNE0yODBizszN M4TlPVLjiImq MUDpcoR2[2W|IIDyc4R2[3Srb36gc4bDqM7|SELBXC=> NF\wbZgzPTB6OEKwNy=>
MCF7 EV NXX6UHJTTnWwY4Tpc44hSXO|YYm= MVuxNE0yODBizszN M3zwb|LjiImq MnLHSXRQWCCrbnT1Z4V{KEGWTTDhZ5RqfmG2aX;u MnKxNlUxQDh{MEO=
MCF7 BMI1 M3T4WmZ2dmO2aX;uJGF{e2G7 NVH1R5NmOTBvMUCwJO69VQ>? MUmy5qCKcA>? NXnuSGNVTVSRUDDpcoR2[2W|IFHUUUBi[3SrdnH0bY9v MX6yOVA5QDJyMx?=
HepG2 NWnCfFZPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjEUXNQyqB? NIDTPHZKSzVyPUOwMlE3yqEEsdMgNE42OMLizszN MnLNNlUxPzh|MUG=
MOLT-3 NV3jbGs6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zTbGROW00EoB?= NGS3Z2pKSzVyPUCuNFUyyqEEsdMgNE4xODMEoN88US=> NFT6WGMzPTB5OEOxNS=>
HT1080 MnnLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{O0XVEuOTByIN88US=> M1u1dlQwOjRxNEigbC=> NYDpT|lxTE2VT9Mg NUTlNYJjcW6mdXPld{Bk\WyuIHTlZZRpKHOrZ37p[olk[W62bImgbY4h[SC4ZYL5JIxwfyClb37j[Y51emG2aX;u NFrxUoEzPTB5OEC2OC=>
HT1080 MnjZSpVv[3Srb36gRZN{[Xl? NWjlblFLOC5yMECxMVExOCEQvF2= MX:xMVI1KGh? MWrEUXNQyqB? NYXB[Vh1cW6mdXPld{BxNXB3Mzjz[ZIyPSliaX6gZo91cCC2aX3lMUBidmRiY3;uZ4VvfHKjdHnvck1l\XCnbnTlcpQhdWGwbnXy NEfMdpAzPTB5OEC2OC=>
HT1080 NHG1e4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGrJdGUxNjByMEGtNVAxKM7:TR?= NWHnZo5nOjRiaB?= MoW1SG1UV8Li MmLqZ4F2e2W|IHHuJIlv[3KnYYPlJIlvKHSqZTDueY1j\XJib3[gZ4VtdHNiaX6gS|IwVSxid3jpcIUh\GWlcnXhd4lv\yCVIHHu[EBIOSCyaHHz[UBk\Wyucx?= Ml3lNlUxPzhyNkS=
HD-MY-Z NIfKTZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTwNlQwPDhxN{KgbC=> MkjTTWM2OO,:nkGwNEDPxE1? M1HVSlI2ODR6MkO2
DOHH-2 M4\ic2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmDPNlQhcA>? M3LxNGlEPTExvK6xNFAh|ryP NUGxVoJ[OjVyNEiyN|Y>
DOHH-2 NGf4RXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1nCVlQ5KGh? MXXJR|UxRTF7LkpCpO69VQ>? MX[yOVA1QDJ|Nh?=
DOHH-2 NFuxNVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjUO|IhcA>? MVjJR|UxRTYEoN88US=> M2[4S|I2ODR6MkO2
REH M3f6fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHtNlQhcA>? M4GyOmlEPTB;MD6wNlfDqM7:TR?= Mon6NlUxPDh{M{[=
REH MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGTQXYQ1QCCq NYHQW3pMUUN3ME2wMlAyPMLizszN NIDQcpIzPTB2OEKzOi=>
REH MoL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHRO|IhcA>? M3LVWWlEPTB;MD6wNVXDqM7:TR?= MYSyOVA1QDJ|Nh?=
HH NYPseoM3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVmyOEBp NX7tOmI{UUN3ME2xNFQvP8LizszN NUnHN4F6OjVyNEiyN|Y>
HH NXHlSodKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2HwZ|Q5KGh? NVmxWHMzUUN3ME20PE43yqEQvF2= MoezNlUxPDh{M{[=
HH M3\PSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU[2UIZIPzJiaB?= MoG4TWM2OD1zND63xsDPxE1? M1XnWVI2ODR6MkO2
HuT-78 M1P3fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4XEZVI1KGh? NYTOSI11UUN3ME25MlPDqM7:TR?= NWrXS|lWOjVyNEiyN|Y>
HuT-78 M3HxV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWG0PEBp MV\JR|UxRTRwM9Mg{txO NE\TU40zPTB2OEKzOi=>
HuT-78 MnnNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4rsOlczKGh? MW\JR|UxRTRwMtMg{txO NE\WS4IzPTB2OEKzOi=>
OPM-2 NHjUfFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDr[5EzPCCq MmXJTWM2OD1{ND6xxsDPxE1? MUeyOVA1QDJ|Nh?=
OPM-2 NUnNTW13T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4Dw[FQ5KGh? MoLiTWM2OD12wrFOwG0> NGTIXmIzPTB2OEKzOi=>
OPM-2 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2XoW|czKGh? NWDLXWVzUUN3ME2xMlPDqM7:TR?= MYiyOVA1QDJ|Nh?=
RPMI-8226 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\ZTIZGOjRiaB?= NX[2W3V1UUN3ME2xNFYvPsLizszN MmWxNlUxPDh{M{[=
RPMI-8226 NH;PV4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU[0PEBp MorrTWM2OD17MT6xxsDPxE1? NF7xN2ozPTB2OEKzOi=>
RPMI-8226 MlXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoHKO|IhcA>? NV;sOFY{UUN3ME2xOE46yqEQvF2= MnvjNlUxPDh{M{[=
U-266 MnzyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NInjSGczPCCq MlvOTWM2OD16Nj6yxsDPxE1? NW[yfnBwOjVyNEiyN|Y>
U-266 NGGwOWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUe0PEBp NEHObHZKSzVyPU[4MlTDqM7:TR?= MmHiNlUxPDh{M{[=
U-266 M1;RSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXi3NkBp MY\JR|UxRTJ5LkVCpO69VQ>? Mn7rNlUxPDh{M{[=
Kelly MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYTvWGlNOC1zMDFOwG0> NX;CRol2PzMEoHi= MmXNTWM2OD1zLkWxPOKh|ryP MnyxNlUxODh7MEC=
SH-SY5Y  NWj6enNLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\l[|BsOC1zMDFOwG0> MX[3NuKhcA>? MXrJR|UxRTBwN{W0xsDPxE4EoB?= MUSyOVAxQDlyMB?=
SK-N-AS MnzRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4PSXFAuOTBizszN MnuyO|LDqGh? MWDJR|UxRTFwN{GyxsDPxE4EoB?= M3j1N|I2ODB6OUCw
SK-N-DZ MnXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVOwMVExKM7:TR?= M1[4OVczyqCq NWTCN4JOUUN3ME21MlQ5PcLizszN M{e4SFI2ODB6OUCw
HepG2 NEnGeGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFTHUWI1QMLiaB?= MnXnSG1UV8Li MY\JR|UxRTF|Lk[1xsDDucLiMD65NuKh|ryP MmC5NlQ6QTZzM{[=
A549 M1XaN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3zZPVQ5yqCq NYHmdZg1TE2VT9Mg NHLT[FhKSzVyPUK0NU46yqEEsdMgN|EvOjQEoN88US=> NE\6TlMzPDl7NkGzOi=>
MCF7 M{jsT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWjrcZh7PDkEoHi= NUS2UplOTE2VT9Mg MnzhTWM2OD16MT6wPeKhyrIEoEG0MlIyyqEQvF2= M{W0dFI1QTl4MUO2
HL-60  MlK2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jWRVczyqCq NH7sVmhKSzVyPUCuNVLjiIYQvF2= NGTOUJIzPDl7M{CxOC=>
HL-60[R] MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2D4NFczyqCq NX\zRXFWUUN3ME2zMlEz6oDHzszN NHfQUZYzPDl7M{CxOC=>
MIAPACA NYHZRpJOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfHTVUxRTFwMzFCtUAxNjB|IN88US=> M1zjXVI1QTV|OEKx
MCF-7 NGPZ[XpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkG5S2k2OD1yLkK1JOKyKDBwMTFOwG0> NEP3ZYEzPDl3M{iyNS=>
HeLa NYD2[WIzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XCeGdKPTB;MD62OEDDuSByLkSg{txO NVHqb251OjR7NUO4NlE>
MO59K  MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHPQVII4KGR? M4rqcGlEPTB;MD6xO-KBjc7:TR?= NETLcpkzPDl3M{W2NS=>
MO59J MlvZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYC3JIQ> MnzlTWM2OD1yLkJihKXPxE1? NHq2VIIzPDl3M{W2NS=>
ME 180 NIG2SndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHiyPGQ1QMLiaNMg MmTvTWM2OD16LkpCpOKyyqByLkRihKXPxE1? NF20PGEzPDl3M{CyOy=>
MCF-7 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYC0POKhcMLi M3PDOWlEPTB;MkOuPUDDuSByLkRihKXPxE1? M3:wSlI1QTV|MEK3
HeLa NGfSZYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYS0POKhcMLi NHzKNllKSzVyPUSuO|EhyrFiMT605qCG|ryP MlLDNlQ6PTNyMke=
MDA-MB-453 Mn65S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\nVVQ5yqCqwrC= MUDJR|UxRTF{LkWgxtEhOC56NfMAie69VQ>? MnG0NlQ6PTNyMke=
MDA-MB-231 MmPoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlP4OFjDqGkEoB?= MkjRTWM2OD1{ND6yNkDDuSB{Lkm05qCG|ryP NXqwUYJNOjR7NUOwNlc>
PC-3 NHvOO4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo[3OFjDqGkEoB?= NFLueHZKSzVyPUG0MlQhyrFiMz6yN-KBjc7:TR?= MoPoNlQ6PTNyMke=
HT-29 M2iwVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWO0POKhcMLi NG\FfJZKSzVyPUKxMlQ2KMLzIEOuPFfjiIYQvF2= M2\Oe|I1QTV|MEK3
BGC-823 M3nObGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGry[Hk1QMLiaNMg M1:2bGlEPTB;NEOuO|QhyrFiNT6xN-KBjc7:TR?= MXmyOFc6Ozh5Nx?=
HeLa NGPoSohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;OZXU1QMLiaNMg NULSN|NOUUN3ME2yNFkvQTBiwsGgNVMvPDJi4pEF{txO MlniNlQ4QTN6N{e=
A549 M13WXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn20OFjDqGkEoB?= Ml[3TWM2OD1zM{muOVQhyrFiNz6wOgKBjc7:TR?= MXiyOFc6Ozh5Nx?=
HK-2 MnnOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4nvWFQ5yqCqwrC= MkeyTWM2OD17LkG3JOKyKDFwNUlihKXPxE1? NX;uUI8xOjR5OUO4O|c>

... Click to View More Cell Line Experimental Data

In vivo Etoposide administrated as a single agent is found to been ineffective in many xenografts growth, such as Heterotransplanted Hepatoblastoma NMHB1, and NMHB 2, [6] human neuroblastoma xenograft, [7] and human gastrointestinal cancer xenograft, [8] while the dose of 10 mg/kg i.p. Etoposide inhibits murine angiosarcoma cell ISOS-1 tumors in 36% of controls. [2] Etoposide induces tumor immunity in Lewis lung cancer. A single administration of 50 mg/kg Etoposide i.p., induces a 60% survival of C57B1/6 mice injected with Lewis lung cancer cell (3LL) over 60 days. About 40% of these surviving mice reject a subsequent challenge with 3LL, while none of control mice survive beyond 30 days. 3LL cells which have survived an 90% lethal concentration of Etoposide in vitro kill 75% of recipient mice, but 60% surviving mice reject challenge with 3LL. Splenocytes harvested from tumor rejecting mice protect naive mice injected with 3LL. [9]

Protocol

Kinase Assay:[5]
+ Expand

Topoisomerase II activity assay:

Nuclear extracts are prepared, and nuclei are isolated. The activity of topoisomerase II is calculated from the percentage of decatenation obtained. Tritiated kinoplast DNA (KDNA 0.22 μg) is used as a substrate. Etoposide and topoisomerase II are incubated for 30 min at 37 ℃ and are stopped with 1% sodium dodecyl sulfate (SDS) and proteinase K (100 μg/mL). The percentages of decatenation and inhibition of topoisomerase II by Etoposide are obtained.
Cell Research:[5]
+ Expand
  • Cell lines: Human glioma cell lines CL5
  • Concentrations: 80 μg/mL
  • Incubation Time: 1 hour
  • Method: After the Etoposide treatment, cells are removed from the dish with phosphate-buffered saline (PBS) containing 0.03% trypsin and 0.27 mM ethylenediaminetetraacetic acid (EDTA) and are diluted into culture dishes in appropriate numbers to yield between 20 and 200 colonies. After 12 days, cultures are fixed with methanol-acetic acid, stained with crystal violet, and scored for colonies containing more than 50 cells. The standard errors are typically less than 15% of the mean value unless otherwise stated.
    (Only for Reference)
Animal Research:[2]
+ Expand
  • Animal Models: Murine angiosarcoma xenografts ISOS-1
  • Formulation: Saline
  • Dosages: 10 mg/kg
  • Administration: i.p. every day for 5 days from day 7
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (169.9 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo 30% propylene glycol, 5% Tween 80, 65% D5W 30 mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 588.56
Formula

C29H32O13

CAS No. 33419-42-0
Storage powder
in solvent
Synonyms VP-16, VP-16213

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03036904 Not yet recruiting Diffuse Large B-Cell Lymphoma|High Grade B-Cell Lymphoma Weill Medical College of Cornell University|Genentech, Inc.|Massachusetts General Hospital|M.D. Anderson Cancer Center February 6, 2017 Phase 1
NCT02432274 Recruiting Tumors|Solid Malignant Tumors|Osteosarcoma|Differentiated Thyroid Cancer (DTC) Eisai Limited|Eisai Inc. December 29, 2014 Phase 1|Phase 2
NCT02385110 Recruiting Leukemia M.D. Anderson Cancer Center September 23, 2015 Phase 2
NCT03007147 Not yet recruiting B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1|BCR-ABL1 Fusion Protein Expression|Minimal Residual Disease|Philadelphia Chromosome Positive|T Acute Lymphoblastic Leukemia|Untreated Adult Acute Lymphoblastic Leukemia|Untreated Childhood Acute Lymphoblastic Leukemia Childrens Oncology Group|National Cancer Institute (NCI) July 2017 Phase 3
NCT03016871 Not yet recruiting CD (Cluster of Differentiation) 30-Positive Neoplastic Cells Present|Recurrent Hodgkin Lymphoma|Refractory Hodgkin Lymphoma City of Hope Medical Center|National Cancer Institute (NCI) June 2017 Phase 2
NCT03041311 Not yet recruiting Small Cell Lung Cancer G1 Therapeutics, Inc. May 2017 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Topoisomerase Signaling Pathway Map

Related Topoisomerase Products

Tags: buy Etoposide | Etoposide supplier | purchase Etoposide | Etoposide cost | Etoposide manufacturer | order Etoposide | Etoposide distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID